Bispecific Antibody Production

In the current competitive biotherapeutic market, predominantly driven by antibody molecules, bispecific antibodies represent a key component of the next generation of antibody therapy - requiring advanced antibody production services to support their development and scalability. Immunoglobulin G (IgG), the most common type of antibody found in blood circulation, are monospecific and recognize only a single antigen, with the exception of IgG4. In contrast, bispecific antibodies are designed to recognize and bind to two different targets.

This is useful as a therapeutic as they can be designed to redirect, for instance, immune cells such as T cells, to selectively engage and eliminate target tumor cells, by allowing effective binding of tumor cell receptors while also recruiting cytotoxic immune cells. In addition, bispecific antibodies can assist in the delivery of therapeutic payloads, such as toxins or drugs, to specific sites in the body.

There are several approaches to producing bispecific antibodies, with the common methods being:

• Knobs-in-holes

• Ig-scFv fusion

• Diabody-Fc fusion

• Dual-Variable-Domain-IgG

Biointron has expressed thousands of bispecific antibodies, and we have extensive experience in bispecific antibody production. We take pride in our ability to cater to any client request, offering a wide array of formats in bispecific antibody production.